VYNE News
Archived Headlines
- Itching for an IPO: Menlo Therapeutics increases proposed IPO deal size and raises the range 01/23/18
- US IPO Week Ahead: 10 IPOs expected to price, led by PagSeguro's $1.8 billion deal 01/19/18
- Dermatology biotech Menlo Therapeutics sets terms for $85 million IPO 01/12/18
- US IPO Weekly Recap: no IPOs during holiday week 12/29/17
- Menlo Therapeutics, a dermatological indication-focused biotech, files for a $98 million IPO 12/28/17
Big biotech swings: 2016 IPO AveXis pops 82%, 2018 IPO Menlo drops 77%
• Recent acquisitions and clinical trial stumbles show the high-risk, high-return nature of biotech IPOs. Betting on a biotech buyout... The billion-dollar biotech buyouts continue. News broke on Monday that Novartis agreed to buy gene therapy...read more
Biotechs take the podium with the year's 3 best IPOs
Biotechs hold gold, silver and bronze in the 2018 IPO market. Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech Menlo Therapeutics ...read more
US IPO Week Ahead: Look for a wave of filings in a quiet holiday week with 2 IPOs
Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move through the annual mid-February lull...read more
Anti-itch biotech Menlo Therapeutics prices IPO at $17, the high end of the range
Menlo Therapeutics, which is developing treatments for moderate to severe skin itch and chronic cough, raised $119 million by offering 7 million shares at $17, the high end of the range of $16 to $17. Menlo Therapeutics plans to list on the Nasdaq under the...read more